5 Benefits of Going Xeno-Free and Products to Look Out For

November 29th at 15:00pm GMT

Challenges This Webinar Will Address:

Xeno-free products are paving the way to change the way science uses media. Here are just a few of the benefits of shifting your media use to xeno-free can have: Reduce the use of agricultural land No more animal slaughter Reduced CO2 emissions Faster growth time versus raising animals Uses less water Aid in the power to transform the world that we live in;
Go xeno-free. Choosing Xeno-Free products will lead to reducing agricultural land use, ceasing animal slaughtering, and reducing C02 emissions and water usage.
CellShip®: Our fully defined, xeno-free cell storage and transportation medium. Our new product provides an alternative to cryopreservation for the transport and short-term storage of mammalian cell lines at ambient temperature for up to 120 hours.
T-STORE ® is an innovative, sterile, chemically defined and optimised tissue media. It has been developed to provide a stable storage and shipping environment for mammalian tissue samples. The product has been designed to maintain the integrity of tissue samples, thereby reducing necrosis and apoptosis. CellSplit®, a completely xeno-free, non-recombinant alternative to porcine or bovine-derived trypsin used during the sub-culturing of adherent cells. It is of plant origin and manufactured as a GMP-grade product.
CellSplit® offers simplicity to its application, whether directly acting as a substitute for trypsin or as an alternative cell dissociation reagent, ultimately reducing any disruption to your current processes.
NeuroPlex™ Serum-Free Neuronal Medium is intended for the long-term culture and maintenance of central nervous system cells. This specialized medium is intended for supplementation with Gem21 NeuroPlex™ or N2 NeuroPlex™, depending upon targeted cell type.

Speakers

Michel Mrad

Marketing Communication and Strategy

Key Takeaways

Dr. Greg Moakes, PHD, Executive Vice President, Business Development

Greg Moakes is Executive Vice President of Business Development for LTS Lohmann Device Technologies LTD. Greg holds a Ph.D. In Chemistry from the Georgia Institute of Technology and an MBA from Southern Methodist University. His career had been focused on drug delivery, first specializing in solid implant dosage formulations and more recently high volume subcutaneous delivery via On-body Delivery Systems.

Dr Kristian Le Vay, Expert Scientist at Coriolis Pharma

Kristian Le Vay is an Expert Scientist at Coriolis, with a focus on novel methods for the developability assessment for biologics. He is a chemist by training with a diverse research background, encompassing the biophysical characterization of complex biomolecules, and the development of advanced therapeutics and drug delivery vectors. He completed his PhD at the Bristol Centre for Functional Nanomaterials (BCFN), University of Bristol, UK, where he developed a keen interest in biophysical method development. Following this, he studied nucleic acid condensation and stability as a postdoctoral scientist at the Max Planck Institute for Biochemistry, Munich, before joining Coriolis in 2022.

Dr. Andrea Hawe, Chief Scientific Officer at Coriolis Pharma

Andrea Hawe is the Chief Scientific Officer at Coriolis. She is an expert in drug product development for biologics with a strong scientific background in protein formulation, surfactant and particle characterization, and lyophilization process technology. Andrea has published more than 40 peer-reviewed papers and book chapters.

Andrea is a pharmacist with a PhD in Pharmaceutical Technology from the LMU Munich. After her PhD, she continued her career as a postdoctoral scientist at the Leiden Academic Center for Drug Research (LACDR) in Leiden (The Netherlands). She was awarded a Veni Fellowship (NWO, The Netherlands) to develop novel approaches for aggregate analysis. She joined Coriolis from the very beginning as a member of the founding team and has been supporting the company since 2008.